



iRIS Reference Number 338357

Amendment Letter: A
IRB Number: 11CN206
Version Date: 07/11/2014

07/11/2014

TO: Qing Lan

FROM: Chairperson, Special Studies Institutional Review Board, NCI

SUBJECT: Action on Clinical Research Protocol Amendment

Your amendment to protocol, "A multi-center international hospital-based case-control study of lymphoma in Asia (AsiaLymph)," was reviewed by the National Cancer Institute Special Studies Institutional Review Board (NCI-SSIRB) by expedited review.

The SSIRB has taken the following action:

X	Approved as written. Forwarded to the CC OPS for administrative processing.
	Approved with stipulations pending re-review by SSIRB Chair. See review comments.
	Deferred pending response to stipulations and re-review by a subcommittee of the Board. See review comments.
	Tabled pending response to stipulations and re-review by the full SSIRB. See review comments.

RE: Increase the accrual level by 3,800 study subjects in addition to the currently approved 6,600 study subjects, for a new accrual ceiling of 10,400.

PI Name: Qing Lan

Protocol Title: A multi-center international hospital-based case-control study of lymphoma in Asia (AsiaLymph)

Stipulations:

Recommendations: